spacer
home > epc > autumn 2003 > central and eastern europe: quality and quantity
PUBLICATIONS
European Pharmaceutical Contractor

Central and Eastern Europe: Quality and Quantity

Speed to market is more important than ever, with enormous pressures on the pharmaceutical industry to develop and produce novel therapies as quickly as possible. To avoid delays, pharma are increasingly using sites in Central and Eastern Europe to boost patient recruitment. Impressive recruitment rates can lead multinational pharmaceutical companies to view the quality of the data with caution. Our experience has shown that both quantity and quality are achievable.

When considering Central and Eastern Europe (CEE), with its array of cultures and languages, there must be no impression that this is one homogeneous region. Following radical political and economic changes, which have not only affected the pharmaceutical industry but health care management too, pharma have recognised the potential in CEE countries for conducting international clinical research.

Over the last two decades there has been a substantial increase in pharmaceutical sponsored clinical trials. This has resulted in the formation of clinical research organisations (CROs) who have developed expertise in CEE countries, working according to good clinical practice (GCP). Local monitors are usually highly motivated and well-educated medical professionals who are native to the country in which they work. Many monitors are medical doctors and are fully acquainted with local health care systems and national regulations. As medical professionals, they are fully conversant with local medical practices and can therefore easily liase with investigators at their professional level.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Nicky Dodsworth, Director of Quality Assurance at Pharm-Olam International (UK) Ltd

Nicky Dodsworth is Director of Quality Assurance at Pharm-Olam International (UK) Ltd, a CRO specialising in setting up, monitoring and project managing clinical studies in Central and Eastern Europe. She has been involved in clinical research and quality systems activities since the mid-1980s, in both pharmaceutical and contract research organisations (CROs).

spacer
Nicky Dodsworth
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI China opens with analysis pointing to a surge in growth in 2019

Shanghai, 23rd May 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement